Physician profile

Navin Ramani

Pain Medicine (Anesthesiology) · Havertown, PA

NPI 1982066403

$3,103.88

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,036.49

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $1,410.92 2022-2024 Proclaim, Eterna, Octrode
Vertos Medical, INC. $522.94 2021-2023 Mild Device Kit
Boston Scientific Corporation $377.86 2021-2023 Wavewriter Alpha Prime 16
Medtronic, INC. $369.23 2021-2023 Intellis Adaptivestim
Si-Bone, INC. $206.35 2022-2023
Nevro Corp. $148.13 2021
Electronic Waveform Lab, INC. $47.11 2023
Saluda Medical Americas, INC. $21.34 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Navin Ramani

$3,103.88

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbott Laboratories

https://glasscript.com/doctor/9333129/navin-ramani

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.